USA flag logo/image

An Official Website of the United States Government

POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7184
Program Year/Program:
1987 / SBIR
Agency Tracking Number:
7184
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MOLECULES FOR HEALTH, INC.
800 E. LEIGH STREET SUITE 206-7 RICHMOND, VA 23219 1534
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1987
Title: POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY. THIS REACTION, THEREFORE, REPRESENTS A LOGICAL TARGET FOR CANCER CHEMOTHERAPY. IN RESPONSE TO THE NEED FOR AN EFFECTIVE AGENT AT THIS SITE, A SERIES OF RIBONUCLEOTIDE REDUCTASE INHIBITORS, BASED ON A VICINAL POLYHYDROXYPHENYL STRUCTURE, HAS BEEN DEVELOPED. THE COMPOUND OF THE INITIAL SERIES WITH THE BEST ANTITUMOR ACTIVITY IN ANIMAL TUMOR MODELS, DIDOX, HAS ENTERED HUMAN CLINICAL TRIALS. THE PURPOSE OF THIS PROPOSAL IS TO DEVELOP AN EVEN MORE EFFECTIVE AGENT OF THIS TYPE. SPECIFICALLY, MOLECULES FOR HEALTH, INC. WILL ADD SUBSTITUENTS TO KNOWN ACTIVE STRUCTURES IN SEVEN CLASSES OF POLYHYDROXYPHENYL COMPOUNDS TO ENHANCE BINDING ON THE ENZYME. STRUCTURAL REQUIREMENTS FOR OPTIMUM ACTIVITY WILL BE EVALUATED. TO OCCOMPLISH THIS,MOLECULES FOR HEALTH, INC. WILL MEASURE THE DEGREE OF ENZYMEINHIBITION, THE RATE OF FREE RADICAL SCAVENGING (MECHANISM OF INHIBITION), AND THE ANTITUMOR ACTIVITY IN THE L1210 LEUKEMIA MODEL. ADDITIONALLY, THE NATIONAL CANCER INSTITUTEWILL BE PROVIDED WITH ADEQUATE QUANTITIES OF THE MOST PROMISING COMPOUNDS FOR FURTHER ANTITUMOR TESTING. AN IMPROVED UNDERSTANDING OF STRUCTURAL FEATURES WILL GIVE DIRECTION TO FURTHER DEVELOPMENT. SUCCESSFUL COMPOUNDS RESULTING FROM PHASE I WILL UNDERGO PHARMACOKINETICS AND TOXICOLOGICAL EVALUATION IN PHASE II.

Principal Investigator:

Bart van't riet phd
8046448591

Business Contact:

Small Business Information at Submission:

Molecules For Health Inc
3313 Gloucester Road Richmond, VA 23227

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No